Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.

Original languageEnglish
Pages (from-to)1625-1629
Number of pages5
JournalAmerican Journal of Cardiology
Volume100
Issue number11
DOIs
Publication statusPublished - 2007 Dec 1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients'. Together they form a unique fingerprint.

  • Cite this